ArticleNature communications2025
Sex-specific role of the 5-HT
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.Translational psychiatry · 2026Review
- Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration.International journal of molecular sciences · 2026Review
- A Single Dose of a Psychedelic Drug Repairs Prefrontal Cortex Synaptic Physiology in a Mouse Model of Prenatal Alcohol Exposure.Brain and behavior · 2026Article
- Pretreatment with the psychedelic DOI mitigates LPS-induced hippocampal inflammation and behavioral impairments in mice.BMC neuroscience · 2026Article
- Prenatal and postnatal effects of gestational immune activation on synaptic and neurodevelopmental pathways via epigenetic mechanisms.Translational psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Alaina M JasterDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Thomas M Hadlock *Department of Chemical Engineering, Virginia Tech, Blacksburg, VA, USA.
Belle Buzzi *Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0003-0031-7377
Jessica L MaltmanDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0009-0004-4469-745X
Gabriella M SilvaPharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0001-6293-1052
Somdatta SahaDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Eda KoseliPharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0002-4812-4024
Abby M PondelickPharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0009-0001-6250-105X
Nikita ThakurDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Xin ZhangDepartment of Chemical Engineering, Virginia Tech, Blacksburg, VA, USA.
Gaoshan LiDepartment of Chemical Engineering, Virginia Tech, Blacksburg, VA, USA.
Sandra Ledesma-CorviDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Karah N MooreDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Hannah R PetersonPharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.
Barbara FujitaDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Alexia L ZylkoDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Melissa R LewisDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA.
Justin L PoklisPharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.
Matthew S HalquistPharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.
Jennifer T WolstenholmePharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0003-3812-9312
Dana E SelleyPharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0003-3118-9339
Peter J HamiltonAnatomy and Neurobiology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0002-6819-8346
Chang LuDepartment of Chemical Engineering, Virginia Tech, Blacksburg, VA, USA. changlu@vt.edu.ORCID http://orcid.org/0000-0003-0181-5888
M Imad DamajPharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA. m.damaj@vcuhealth.org.
Javier González-MaesoDepartments of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA. javier.maeso@vcuhealth.org.ORCID http://orcid.org/0000-0003-3105-3204
Funding
Project 5 - Genetic architecture of alcohol use disorder using cross-trait genetic correlations and public next-generation sequencing studiesP50AA022537 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MICHAEL F MILES · 2014 to 2026
$19.6MTRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7MVCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Matthew Sean Halquist · 2014 to 2026
$13.8MStructure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8MVirginia Commonwealth University Postbaccalaureate Research Education ProgramR25GM089614 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI Rebecca Kelley Martin · 2010 to 2026
$4.9MLow-input profiling of brain-region and cell-type specific epigenomic dynamics to understand gene-environment interactions in opioid addictionR01DA056187 · NIDA · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Julie A Blendy, Chang Lu · 2023 to 2026
$2.8MPreclinical role of HDAC2 in mGlu2-dependent schizophrenia treatmentR01MH111940 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI GONZÁLEZ-MAESO, JAVIER · 2017 to 2021
$1.5MReprogramming KZFP function to understand drug-specific transcription and behaviorR01DA058089 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Peter James Hamilton · 2024 to 2026
$1.5MDroplet microfluidic technology for single-cell epigenomic and multi-omic profilingR01GM143940 · NIGMS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI LU, CHANG · 2021 to 2024
$1.3MMolecular target and circuitry underlying the preclinical effects of psychedelics in models of opioid use disorderF31DA057818 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI JASTER, ALAINA · 2023 to 2023
$39kNIAAA NIH HHS P50 AA022537NIDA NIH HHS F31 DA057818NIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA056187NIDA NIH HHS R01 DA058089NIDA NIH HHS T32 DA007027NIGMS NIH HHS R01 GM143940NIGMS NIH HHS R25 GM089614NIMH NIH HHS R01 MH084894NIMH NIH HHS R01 MH111940U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01GM143940U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R25GM089614U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH084894U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH111940U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) R01AA022537U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) F31DA057818U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) P30DA033934U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) R01DA056187U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) R01DA058089U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) T32DA007027
Abstract
Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid use disorder (OUD) by alleviating key hallmarks such as altered reward processing and dependence. However, the mechanisms behind these effects remain unclear. Our data demonstrate that a single administration of the psychedelic psilocybin (PSI) reduces conditioned behavior and withdrawal induced by the opioid oxycodone (OXY) in male mice but not in females, and this effect is mediated via the 5-HT
Indexed as
Analgesics, OpioidExtinction, PsychologicalPsilocybinReceptor, Serotonin, 5-HT2ARewardAnimalsEpigenesis, GeneticFemaleFrontal LobeHallucinogensMaleMiceMice, Inbred C57BLNucleus AccumbensPyramidal CellsSex CharacteristicsAnalgesics, OpioidHallucinogensPsilocybinReceptor, Serotonin, 5-HT2A
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.